EMA launches 'urgent safety review' of alemtuzumab after two patient deaths
The European Medicines Agency (EMA) has launched a safety review of alemtuzumab following reports of two deaths and several other cases of people experiencing life-threatening reactions shortly after taking the medicine.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | European Medicines Agency (EMA)